Improved vascularization of porous scaffolds through growth factor delivery from heparinized polyethylene glycol hydrogels
Source abstract
Abstract
Surface modification with heparin has previously been shown to increase vascularization of porous scaffolds. In order to determine its efficacy with sustained release, heparin (Hep) was covalently incorporated into degradable (Type D) and non-degradable (Type N) polyethylene glycol (PEG) hydrogels. After in vitro characterization of their physicochemical properties, growth factor (GF) loaded, heparinised Type D gels were formed within the pores of porous polyurethane disks, which were then implanted and evaluated in a subcutaneous model. Type N gels formed faster (3.1±0.1 vs. 7.2±0.2min), were stiffer (10.0±0.5kPa vs. 7.1±1.2kPa) and more stable than degradable gels (>6month stability vs. disintegration ⩽22d in vitro; all p<0.001). Sustained release of covalently incorporated (CI) heparin from Type N (56days; first order kinetics) and Type D (21days; zero order kinetics) was achieved, as opposed to non-covalently incorporated (NI) heparin that eluted in a burst release within the first 2days. While Type D gels initially impeded tissue ingrowth into the porous scaffolds, they were completely degraded and replaced by ingrown tissue after 28days in vivo. At the latter timepoint disks containing gels without Hep or with non-covalently incorporated Hep were less vascularized than empty (no gel) controls. In contrast, the incorporation of covalently heparinized (no GF) and GF containing gels (no Hep) resulted in a 50% and 42% (p<0.05) improvement in vascularization, while an increase of 119% (p<0.001) was achieved with a combination of covalently attached Hep and GF. These gels thus provide a sustained release system for heparin and GF that extends the duration of their action to local tissue ingrowth. Statement of significance The paper describes the modification and covalent incorporation of heparin into degradable and non-degradable polyethylene glycol hydrogels in a way that provides for the hydrolytic cleavage of the linker for the release of the heparin in original and active form, and in an extended (21-56d) controlled (zero and first order respectively) manner. The successful use of these gels as growth-factor containing and releasing matrices for the improvement of in vivo vascularization holds promise for many potential uses in tissue engineering and regenerative medicine applications, such as vascular grafts and myocardial infarction therapy, where the antithrombotic and/or growth factor binding/potentiating properties are required.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Hydrogels: synthesis, properties, applications · Wound Healing and Treatments · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (61)
Show source-provided references
1. To engineer is to create: the link between engineering and regeneration10.1016/j.tibtech.2005.10.006 ↗
2. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications
3. VEGF gene delivery to myocardium: deleterious effects of unregulated expression10.1161/01.CIR.102.8.898 ↗
4. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor10.1016/j.biomaterials.2005.03.012 ↗
5. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy10.1111/j.1582-4934.2008.00658.x ↗
6. The anti-inflammatory effects of heparin and related compounds10.1016/j.thromres.2006.10.026 ↗
7. Protein delivery from materials formed by self-selective conjugate addition reactions10.1016/S0168-3659(01)00398-4 ↗
8. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor10.1163/156856206774879090 ↗
9. Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use10.3390/molecules20046342 ↗
10. Covalent surface heparinization potentiates porous polyurethane scaffold vascularization10.1177/0885328208097565 ↗
11. Angiogenic efficacy of Heparin on chick chorioallantoic membrane10.1186/2045-824X-4-8 ↗
12. Heparin and angiogenic therapy10.1053/euhj.1999.1700 ↗
13. Non-anticoagulant heparins and inhibition of cancer10.1159/000175157 ↗
14. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin10.1016/0049-3848(90)90180-K ↗
15. Hydrogels in drug delivery: progress and challenges10.1016/j.polymer.2008.01.027 ↗
16. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling10.1016/j.cardfail.2009.03.003 ↗
17. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth10.1096/fj.02-1041fje ↗
18. The effect of heparin-functionalized PEG hydrogels on three-dimensional human mesenchymal stem cell osteogenic differentiation10.1016/j.biomaterials.2006.08.033 ↗
19. Structural and functional characterisation of poly(vinyl alcohol) and heparin hydrogels10.1016/j.biomaterials.2008.08.011 ↗
20. Functional porous hydrogels to study angiogenesis under the effect of controlled release of vascular endothelial growth factor10.1016/j.actbio.2012.05.019 ↗
21. A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases10.1016/j.biomaterials.2009.06.002 ↗
22. Growth factor delivery from hydrogel particle aggregates to promote tubular regeneration after acute kidney injury10.1016/j.jconrel.2013.01.030 ↗
23. Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants10.1016/j.biomaterials.2003.09.054 ↗
24. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition10.1021/bm025744e ↗
25. Michael addition reactions in macromolecular design for emerging technologies10.1016/j.progpolymsci.2006.03.001 ↗
26. The beneficial effects of deferred delivery on the efficiency of hydrogel therapy post myocardial infarction10.1016/j.biomaterials.2011.11.031 ↗
27. Sustained release of human growth hormone from heparin-based hydrogel10.1021/bm701391b ↗
28. Heparin-based hydrogel as a matrix for encapsulation and cultivation of primary hepatocytes10.1016/j.biomaterials.2010.01.068 ↗
29. Formation of a novel heparin-based hydrogel in the presence of heparin-binding biomolecules10.1021/bm0701189 ↗
30. In situ crosslinkable hyaluronan hydrogels for tissue engineering10.1016/j.biomaterials.2003.08.014 ↗
31. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems10.1016/j.jconrel.2007.04.019 ↗
32. Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells10.1002/jbm.a.34075 ↗
33. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels10.1021/bm050003+ ↗
34. PEGylation, successful approach to drug delivery10.1016/S1359-6446(05)03575-0 ↗
35. Biomaterials for the treatment of myocardial infarction10.1016/j.jacc.2006.06.005 ↗
36. USP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium10.1007/s00216-014-7940-3 ↗
37. Covalent incorporation and controlled release of active dexamethasone from injectable polyethylene glycol hydrogels10.1002/jbm.a.34438 ↗
38. Facile spectrophotometric assay of molar equivalents of N-hydroxysuccinimide esters of monomethoxyl poly-(ethylene glycol) derivatives10.1186/1752-153X-6-142 ↗
39. D.A. Lane, U. Lindahl, Heparin Chemical and biological properties: Clinical Applications, 1989, pp. 25–64.
40. Evidence for 3-O-sulfated d-Glucosamine residue in the antithrombin-binding sequence of heparin10.1073/pnas.77.11.6551 ↗
41. Further characterization of the antithrombin-binding sequence in heparin10.1016/S0008-6215(00)81050-2 ↗
42. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin llland eliciting high anti-factor Xa activity10.1016/0006-291X(83)90550-8 ↗
43. Structure of the Heparan Sulfate-Protein Linkage Region10.1016/S0021-9258(17)38632-5 ↗
44. Molecular distinctions between heparan sulphate and heparin10.1042/bj2300665 ↗
45. Rheological characterization of in situ cross-linkable hyaluronan hydrogels10.1021/bm050361c ↗
46. Light-induced tailoring of PEG-hydrogel properties10.1016/S0142-9612(97)00219-6 ↗
47. Quantitative analysis of N-sulfated, N-acetylated, and unsubstituted glucosamine amino groups in heparin and related polysaccharides10.1016/0003-2697(90)90624-I ↗
48. Effect of well defined dodecahedral porosity on inflammation and angiogenesis10.1097/00002480-200209000-00004 ↗
49. Chemical modification of polysaccharides10.1155/2013/417672 ↗
50. Chemical microdetermination of heparin in plasma10.1006/abio.1997.2277 ↗
51. Hydrolytically degradable poly(ethylene glycol) hydrogel scaffolds with tunable degradation and mechanical properties10.1021/bm100137q ↗
52. Relative reactivity and selectivity of vinyl sulfones and acrylates towards the thiol–Michael addition reaction and polymerization10.1039/C2PY20826A ↗
53. The effect of the linker on the hydrolysis rate of drug-linked ester bonds10.1016/j.jconrel.2003.12.009 ↗
54. The thiol-Michael addition click reaction: a powerful and widely used tool in materials chemistry10.1021/cm402180t ↗
55. Network formation and degradation behavior of hydrogels formed by Michael-type addition reactions10.1021/bm049607o ↗
56. Conformation of heparin studied with macromolecular hydrodynamic methods and X-ray scattering10.1007/s00249-003-0316-9 ↗
57. Controlled release of tethered molecules via engineered hydrogel degradation: model development and validation10.1002/jbm.a.30307 ↗
58. 1976–1983, a critical period in the history of heparin: the discovery of the antithrombin binding site10.1016/S0300-9084(03)00078-6 ↗
59. Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation10.1016/j.actbio.2005.03.002 ↗
60. A light scattering study of the interaction of fibroblast growth factor (FGF) with its receptor10.1529/biophysj.108.129569 ↗
61. Angiogenesis: regulatory role of heparin and related